Plaque Psoriasis

In a post hoc analysis, Green and colleagues examined the effect of halobetasol and tazarotene lotion on plaque psoriasis in a Hispanic population.

Green introduces the combination lotion tested in this clinical trial of patients with moderate-to-sever plaque psoriasis.

Even in trials like UltIMMA that compare 2 drugs, a placebo control grounds the data, says Ken Gordon, MD.

Aside from the efficacy and safety of risankizumab, Gordon addresses the convenience, ease of use, and persistence of efficacy for patients with psoriasis.

Gooderham addresses what the 3-year results of the reSURFACE 2 trial of tildrakizumab for plaque psoriasis mean for prescribers.

The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.

This extension study investigated the long-term efficacy and safety of tildrakizumab for patients with plaque psoriasis.

Results from the reSURFACE 1 phase 3 trial shows the biologic is beneficial to patient rates of anxiety, pain, and depression.

Investigators assessed patients’ scores for body surface area, static Physician Global Assessments, and Dermatology QoL Index at 1 month post-index, and at three-month intervals both pre- and post-index.

In this analysis, brodalumab was successful in treating patients who had a psoriasis diagnosis for

New data from AAD show the recently-approved biologic is among the most cost-saving therapies in year 2 of treatment, and beyond.

An internist’s perspective on which sessions to attend, from melanoma to inflammatory diseases to cosmetic procedures.

The therapy has been approved for use along with the One-Press injector—a device designed to fit comfortably in the patient’s hand and hide the needle through administration.

After nearly a year of therapy, 84.5% of patients treated with guselkumab achieved at least 90% severity index improvement, compared to 70% of those treated with secukinumab.

The FDA has extended the approved use of Bryhali (halobetasol propionate) Lotion .01% for up to 8 weeks in adults with plaque psoriasis.

Novartis reported that 59% of patients at 24 weeks experienced little to no impact of their condition on their quality of life. Additionally, 87% of bio-naïve psoriasis patients remained on secukinumab through 12 months, indicating its tolerability in real-world settings.

The fixed-dose combination therapy from Valeant Pharmaceuticals International is vying to become the first and only approved topical lotion for the condition.

CIMZIA is the first Fc-free biologic of its kind for this patient population.

Taltz (ixekizumab) is the first FDA-approved treatment for moderate to severe plaque psoriasis that includes data on psoriasis in the genital area.

The therapy met all co-primary and ranked secondary endpoints in the 4 trials without displaying any new safety signals, according to AbbVie.

The therapy was approved on the evidence of a pivotal phase 3 clinical development program which tested the efficacy of the inhibitor versus placebo in 926 adult patients.

Patients taking ustekinumab showed a 19% improvement in aortic inflammation compared to placebo.

The label update for secukinumab (Cosentyx, Novartis) now includes the treatment for moderate-to-severe scalp psoriasis.

The Biologics License Application is for another biosimilar to AbbVie's best-selling Humira drug.

The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.

Nearly half of the study participants achieved complete skin at week 16, while 87% maintained the response at week 52.

If approved, this will be the first and only topical lotion that contains a unique combination formula.

The AbbVie investigational drug hit endpoints in 3 pivotal phase 3 trials.

The development of MC2-01 Cream is designed to focus on the acute and long-term needs of patients.

Findings show Janssen's drug led to significant skin clearance results at week 12.